Top Page
Nova Eye Medical
(Sydney:EYE)
Nova Eye Medical (EYE) vs. iShares MSCI Australia ETF (EWA)
Nova Eye Medical Business Overview & Revenue Model
Nova Eye Medical Earnings Call Summary
Nova Eye Medical Financial Statement Overview
| Breakdown | TTM | Jun 2025 | Jun 2024 | Jun 2023 | Jun 2022 | Jun 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 33.05M | 29.27M | 23.32M | 17.02M | 13.38M | 13.39M |
| Gross Profit | 22.05M | 20.07M | 20.19M | 842.00K | -765.00K | 1.77M |
| EBITDA | -3.90M | -8.98M | -5.98M | -14.65M | -7.89M | -3.67M |
| Net Income | -7.03M | -9.06M | -8.79M | -15.29M | -7.50M | -4.36M |
Balance Sheet | ||||||
| Total Assets | 23.67M | 26.50M | 29.88M | 30.36M | 36.63M | 41.99M |
| Cash, Cash Equivalents and Short-Term Investments | 2.62M | 5.05M | 6.15M | 7.42M | 8.00M | 17.80M |
| Total Debt | 4.94M | 3.02M | 3.35M | 1.53M | 1.94M | 3.70M |
| Total Liabilities | 7.85M | 7.54M | 8.55M | 7.17M | 6.23M | 6.66M |
| Stockholders Equity | 15.82M | 18.97M | 21.33M | 23.19M | 30.40M | 35.34M |
Cash Flow | ||||||
| Free Cash Flow | -5.19M | -6.58M | -8.31M | -7.52M | -10.27M | -15.13M |
| Operating Cash Flow | -4.85M | -6.15M | -7.86M | -6.72M | -4.68M | -12.90M |
| Investing Cash Flow | -477.00K | -364.00K | -325.00K | -800.00K | -4.58M | -3.22M |
| Financing Cash Flow | 5.52M | 5.56M | 6.91M | 6.82M | -402.00K | -61.61M |
Nova Eye Medical Technical Analysis
Nova Eye Medical Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
52 Neutral | AU$45.57M | -4.37 | -44.16% | ― | 25.47% | 14.08% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
51 Neutral | AU$25.13M | -2.58 | -103.74% | ― | 14.84% | 39.64% | |
48 Neutral | AU$67.92M | 664.00 | -6.35% | ― | 2.23% | -263.16% | |
44 Neutral | AU$102.52M | -5.34 | -31.98% | ― | 34.20% | -23.90% | |
44 Neutral | AU$163.57M | -15.12 | -70.55% | ― | ― | -257.32% | |
41 Neutral | AU$50.83M | -3.10 | -128.19% | ― | -14.25% | -22.83% |
Nova Eye Medical Corporate Events
Nova Eye Medical will host an investor webinar on 3 March 2026 at 11:30 am AEDT, led by managing director Tom Spurling, to discuss the company’s half-year financial results and operational performance. Shareholders and interested investors can register online and submit questions in advance or during the live Q&A, underscoring the company’s focus on investor engagement and transparency around its progress in the glaucoma treatment market.
The most recent analyst rating on (AU:EYE) stock is a Hold with a A$0.17 price target. To see the full list of analyst forecasts on Nova Eye Medical stock, see the AU:EYE Stock Forecast page.
Nova Eye Medical has released an investor presentation detailing its financial results for the six months ended 31 December 2025, ahead of a March 2026 briefing. The materials underscore the company’s focus on treatments for high intraocular pressure, highlighting the clinical need arising when eye drainage canals become blocked and fluid builds up, ultimately risking optic nerve damage and blindness, which frames the commercial relevance of its glaucoma solutions.
The most recent analyst rating on (AU:EYE) stock is a Hold with a A$0.17 price target. To see the full list of analyst forecasts on Nova Eye Medical stock, see the AU:EYE Stock Forecast page.
Nova Eye Medical reported record half-year revenue of A$16.7 million for the six months to 31 December 2025, equivalent to US$11 million and up 31% in constant currency. Growth was led by the U.S. market and stronger performance in the rest of the world, driving last-twelve-month sales to A$32.2 million, roughly three times the estimated growth rate of the glaucoma surgical devices industry.
The company substantially improved its operating result, narrowing its EBITDA loss to A$2.2 million from A$4.2 million a year earlier on the back of higher gross margins, operating leverage and cost control. Nova Eye achieved positive EBITDA in December 2025, reaffirmed its FY26 guidance for sales of US$21–24 million excluding China, and signalled a path toward breakeven EBITDA in the second half of FY26, underscoring improving cash generation and operating momentum.
The most recent analyst rating on (AU:EYE) stock is a Hold with a A$0.17 price target. To see the full list of analyst forecasts on Nova Eye Medical stock, see the AU:EYE Stock Forecast page.
Nova Eye Medical has re-lodged its FY25 Appendix 4G with the ASX after identifying a single omitted tick-box relating to the availability of corporate governance information on its website. The company stressed that the underlying information was already accessible online and that all other disclosures in the governance key remain accurate and complete, underscoring that this is a minor compliance correction rather than a change to operations or strategy.
The updated filing aligns Nova Eye with ASX corporate governance disclosure requirements and serves to tidy an administrative oversight in its original submission. For investors and regulators, the move signals continued attention to governance transparency and listing rule obligations, with no apparent implications for the company’s financial performance or day-to-day business activities.
The most recent analyst rating on (AU:EYE) stock is a Hold with a A$0.17 price target. To see the full list of analyst forecasts on Nova Eye Medical stock, see the AU:EYE Stock Forecast page.
Nova Eye Medical has scheduled an investor webinar for Monday, 2 February 2026 at 11:30 am AEDT, where Managing Director Tom Spurling will present the company’s quarterly results and provide an update on the iTrack Registry. Shareholders and interested investors can register online and will be able to submit questions ahead of time or participate in a live Q&A during the session, signalling the company’s continued engagement with its investor base and providing greater transparency around the performance and clinical uptake of its glaucoma treatment technologies.
The most recent analyst rating on (AU:EYE) stock is a Hold with a A$0.19 price target. To see the full list of analyst forecasts on Nova Eye Medical stock, see the AU:EYE Stock Forecast page.
Nova Eye Medical reported record global sales of US$6.1 million for the December 2025 quarter, up 38% year-on-year and 25% on the previous quarter, driven by strong demand for its iTrack technology in the US and accelerating growth in other regions. Last-twelve-month sales reached about US$21 million, growing roughly three times faster than the broader industry, while operating cash outflow was A$1.0 million, including a A$1.2 million working capital investment to support rapid sales expansion; management expects operating cashflow to continue improving as utilisation of iTrack grows and new markets such as China begin commercialising the recently approved iTrack Advance during 2026.
The most recent analyst rating on (AU:EYE) stock is a Hold with a A$0.19 price target. To see the full list of analyst forecasts on Nova Eye Medical stock, see the AU:EYE Stock Forecast page.
Nova Eye Medical has reported positive 12‑month clinical outcomes from its iTrack Global Data Registry, an independently managed, prospective real-world database now comprising more than 600 eyes contributed by 20 surgeons across 20 international sites. The latest annual statistical report shows 409 eyes with one-year follow-up, demonstrating an 85% success rate in reducing intraocular pressure in patients with baseline pressure above 18 mmHg and an average 40% reduction in medication use, alongside only six minor, self-resolving adverse events. These results compare favourably with other minimally invasive glaucoma surgery options and are expected to strengthen the clinical and safety case for canaloplasty with iTrack, supporting broader surgical adoption, payer engagement, market access, and future peer-reviewed publications that could further entrench Nova Eye’s position in the glaucoma treatment market.
The most recent analyst rating on (AU:EYE) stock is a Hold with a A$0.19 price target. To see the full list of analyst forecasts on Nova Eye Medical stock, see the AU:EYE Stock Forecast page.
Nova Eye Medical has released a presentation ahead of an investor webinar scheduled to discuss its December 2025 sales results, outlining the clinical context in which it operates by highlighting how blocked ocular drainage canals cause fluid build-up, raised intraocular pressure and eventual optic nerve damage. While the document is largely introductory and framed by standard investment disclaimers, it underscores the company’s focus on addressing glaucoma-related pathology, reinforcing its positioning within the eye-care market as it prepares to update investors on trading performance and the commercial traction of its glaucoma-focused technologies.
The most recent analyst rating on (AU:EYE) stock is a Sell with a A$0.15 price target. To see the full list of analyst forecasts on Nova Eye Medical stock, see the AU:EYE Stock Forecast page.
Nova Eye Medical has scheduled an investor webinar for Monday, 19 January 2026 at 11:30 am AEDT, during which Managing Director Tom Spurling will present a sales update for the six months ended 31 December 2025 and take questions from participants. The event signals an effort by the glaucoma-focused device maker to increase transparency and engagement with shareholders ahead of releasing detailed half-year figures, offering investors an early window into trading performance and operational momentum in its key markets.
The most recent analyst rating on (AU:EYE) stock is a Hold with a A$0.17 price target. To see the full list of analyst forecasts on Nova Eye Medical stock, see the AU:EYE Stock Forecast page.
Nova Eye Medical reported record global sales of US$6.1 million for the December 2025 quarter, up 38% year-on-year and 25% on the previous quarter, driving six‑month revenue to US$10.9 million, a 29% increase on the prior corresponding period. For the twelve months to 31 December 2025, group revenue reached about US$21 million, up 24% and roughly three times the estimated industry growth rate, underpinned by sustained strength in the US market—where iTrack Advance has delivered six consecutive halves of sales growth at an annualised rate of about 40%—and robust gains in Rest of World markets, while China lagged ahead of expected 2026 sales of iTrack Advance following its recent approval. These results, which are subject to audit, highlight Nova Eye’s accelerating market penetration in minimally invasive glaucoma surgery and reinforce its competitive positioning within the sector.
The most recent analyst rating on (AU:EYE) stock is a Hold with a A$0.13 price target. To see the full list of analyst forecasts on Nova Eye Medical stock, see the AU:EYE Stock Forecast page.
Nova Eye Medical Limited has announced the application for the quotation of 12,000 ordinary fully paid securities on the ASX, with an issue date of December 8, 2025. This move is part of an employee incentive scheme and signifies the company’s ongoing efforts to enhance its market presence and operational capabilities.
The most recent analyst rating on (AU:EYE) stock is a Hold with a A$0.13 price target. To see the full list of analyst forecasts on Nova Eye Medical stock, see the AU:EYE Stock Forecast page.
Nova Eye Medical Limited held its Annual General Meeting on 27 November 2025, where all resolutions were carried with significant majorities. The resolutions included the adoption of the remuneration report, the re-election of directors Victor Previn and Daniel Webb, and the approval of an employee incentive plan. The approval of these resolutions reflects strong shareholder support and is likely to positively impact the company’s governance and operational strategies.
The most recent analyst rating on (AU:EYE) stock is a Hold with a A$0.13 price target. To see the full list of analyst forecasts on Nova Eye Medical stock, see the AU:EYE Stock Forecast page.
Nova Eye Medical Limited has made significant strides in the glaucoma surgical devices market with its iTrack™ Advance, achieving a 26% increase in US sales and a record $29.3 million in revenue. The company is expanding globally, with regulatory approval in China and a strong presence in Germany, while enhancing production capabilities to meet growing demand.
The most recent analyst rating on (AU:EYE) stock is a Hold with a A$0.13 price target. To see the full list of analyst forecasts on Nova Eye Medical stock, see the AU:EYE Stock Forecast page.